ArticleCancer cell international2025
Creatine kinase B, a downstream effector of c-Myb, controls migration of osteosarcoma cells via regulation of N-cadherin.
Article in Cancer cell international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundWe have recently identified transcription factor c-Myb as a negative prognostic factor in osteosarcoma (OSA) patients associated with metastatic disease. Transcriptomic analysis identified creatine kinase B (CKB) as one of the most deregulated genes in OSA cell lines with depleted MYB. CKB is a component of the creatine/phosphocreatine system that plays a key role in maintaining cellular energy homeostasis and energy transport to sites with high demand. This study was therefore conducted to investigate the functional significance of CKB in OSA.
methodsDeregulation of CKB by c-Myb in OSA cells was analyzed using gain-of-function/loss-of-function approach. Transactivation of the CKB promoter by c-Myb was assessed using a reporter assay. CRISPR/Cas9, RNAi and cyclocreatine were used to inhibit the expression/activity of CKB in OSA cells. Cell growth, colony-forming capacity, cell migration, chemosensitivity in vitro and metastatic capacity in vivo was examined. CKB protein effectors were identified using liquid chromatography-mass spectrometry (LC-MS) in data-independent acquisition-parallel accumulation serial fragmentation mode.
resultsCKB was validated as c-Myb target in OSA cell lines. Depletion of CKB using CRISPR/Cas9 resulted in slower migration of OSA cells in vitro and reduced metastatic capacity in immunodeficient mice. siRNA and cyclocreatine inhibited OSA cell migration as well but in this case, cell proliferation was also reduced. A total of 8474 protein groups were quantified, with 147 downregulated and 143 upregulated protein groups associated with the CKB knockout phenotype. The deregulated proteins were enriched for those associated with cell migration and motility. N-cadherin, an established regulator of cell migration, was identified as a target of CKB signaling and its role in OSA cell migration and metastasis was confirmed.
conclusionc-Myb - CKB - N-cadherin axis was identified as pathway regulating OSA cell migration and metastasis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.